Lithium metal materials are patented externally.
Graphene Coating only sells manufacturing equipment and does not license patents.
Firmly hold on to those with higher technical content, and license patents for those with less technical content.
This method of operation was thought up by the executives of Kechuang Biotechnology.
They believe that this can maximize the company's interests while ensuring that technology is not leaked.
You can look at my graphene coating structure, but you can’t guess our specific implementation path.
Just like everyone knows what the underlying principle of a lithography machine is, but re-engraving requires a lot of manpower, material resources and time costs.
In the future, graphene coating can continue to be optimized, and after the technology forms certain barriers, it will have an absolute monopoly advantage.
If it can achieve the technical advantages of ASML, Kechuang Biotechnology will have a deeper moat.
Therefore, Kechuang Biotech bought a piece of land in Suzhou and has begun to recruit people as a production base for graphene coating equipment.
In 2022, the profit from endorphins alone will exceed 10 billion yuan. Kechuang Biotech has too much cash lying on its books. It is also a worry to have too much money and not know how to spend it.
Just like MiHoYo, which had too much money on its books and then invested in a company whose main business is controllable nuclear fusion, it still led the Series A round.
There was so much liquidity on the books that the higher-ups wanted Kechuang Biotech to conduct a private placement, but Kechuang Biotech could not find a reason for the private placement for a while.
Gao Minghuan has been working in the industry for many years and quickly understood the plan of Kechuang Biotech. He secretly thought that this separation method can ensure the lower limit of Kechuang Biotechnology in the next twenty years.
New energy is a major trend, and monopolizing one of the indispensable segments can at least provide a steady stream of cash flow.
Endorphins, brain-computer connection and graphene-coated equipment, Gao Minghuan thought about it in his mind, only to find that the other party actually monopolized a lot of areas.
He was shocked in his heart, but kept his expression on the surface: "LG Chem is willing to pay a high price to lock in your company's graphene coating equipment in advance."
Cheng Gang: "Sorry, we have already signed supply agreements with CATL, BYD and other companies. Even if we want to supply manufacturers such as LG Chem, we have to wait until we have excess production capacity."
"If there is any news later, I will inform your company as soon as possible."
...
“Kechuang Bio’s annual revenue is close to 250 billion yuan, of which brain-computer connection revenue accounts for more than the biomedical business.
Its annual non-net profit was around 150 billion yuan, with an average daily profit of 410 million yuan. Its net profit growth rate exceeded 300%, far exceeding expectations, and ranked fifth among listed companies.
This is also the first time in the past decade that a non-financial company has entered the top ten net profit rankings of listed companies in China. "
After Kechuang Biotech's 2022 full-year financial report is expected to be released, Kechuang Biotechnology, which has been exceeding 2 trillion RMB in market value since the opening of the market the next day, once again directly raised the daily limit.
You must know that the market value of Ningde Times, whose net profit is only one-tenth of Kechuang Biotechnology, is 1.1 trillion RMB.
The technological content of Kechuang Biotechnology is higher than that of CATL.
Moreover, there have been repeated reports recently that Kechuang Biotech has entered the lithium battery industry, which has further fueled the further rise of Kechuang Biotech.
"It's so awesome. It's the first time I see such an awesome technology company with a net profit of 150 billion. Monopoly is really very profitable."
A net profit of 150 billion sounds exaggerated, but given a set of data, you will know that this is not the most exaggerated.
Huaguo Tobacco's net profit in 2021 is close to 1.3 trillion yuan, and Huaguo Investment's full-year net profit in 2020 is close to 700 billion yuan.
"Actually, it's not bad. The annual net profit of Goose Factory this year is 196.4 billion RMB, and the market value is only 4 trillion HKD. Kechuang Biotechnology has a market value of 2 trillion to 3 trillion, which is about the same. Those who say the unit price exceeds 10,000 yuan Just shout."
The total share capital of Kechuang Biotechnology is 400 million shares, and the unit price exceeds 10,000, which means that the market value exceeds 4 trillion.
One lot is 1 million, which only institutions can afford.
The target prices of Soochow, CICC, and CITIC Construction Investment are all between 8,000 yuan and 10,000 yuan.
Among them, the title of Soochow is: "Don't be afraid of the clouds covering your eyes, just because you are at the top."
Slightly exaggerated.
"Upstairs, the logic of Kechuang Biotechnology is completely different from that of Goose Factory. They are not the same type of companies. For social traffic, Byte and Goose Factory compete with each other. In terms of cloud services, Ali, Huawei, Qiandu and Goose Factory compete. compete.
Not to mention the gaming field, where there are so many competitors.
Does Kechuang Biotech have competitors in the fields of endorphins and brain-computer connection? Musk's Neuralink can only be used in the mid-range mobile phone market, and its recognition rate is far inferior to that of Kechuang Bio.
The moat of Kechuang Biotech is much deeper than that of Goose Factory. Not to mention that Kechuang Biotech also has two favorable production capacities that have not yet been released: brain-computer connection VR and new lithium battery materials.
In my opinion, the market value of 4 trillion yuan is not the ceiling of scientific and technological innovation at all, but is just a starting point. "
"That's almost it. Science and Technology Biotech is indeed great, but does it have anything to do with us retail investors? Can you afford to buy one?
I worked hard to spend 500,000 yuan in working capital to play on the Science and Technology Innovation Board, but it was only enough to buy one hand of science and technology innovation organisms.
This company does not make money for retail investors, only institutional trading. Just watching it rise, the daily trading volume is ridiculously small. "
"When will Kechuang Biotech be split up? If we don't split it up, retail investors will not be able to enjoy the benefits of corporate development. We also want to grow with great companies!"
Splitting means splitting a stock 10 for 10. This is done when the stock price is too high and is not conducive to trading.
About 30 years ago, there was a ticket called Yuyuan Mall, and its market value increased from 800 yuan to 10,500 yuan.
(As for whether Yuyuan Mall has been split up, I really don’t remember)
“I took a look and found that Kechuang Biotechnology’s R&D investment in the first three quarters reached 60 billion yuan. I estimate that most of it was spent on brain-computer connection chips.
Whether it is the R&D center in England or the aggressive poaching in the field of AI chips this year, the CEO of Cambrian has come out to publicly announce whether he can stop poaching the R&D teams of domestic friends and poach foreign R&D teams. .
There is no other way to get poached. Domestic AI companies have been poached all over the place.
From this point of view, even if the revenue is so high and the moat is so deep, Kechuang Biotech still invests a lot of money in research and development.
This shows the enterprising spirit of the company's management. Zheng Li is only in his twenties now, and his strong enterprising spirit can last at least twenty years.
Coupled with its top-notch research talent, I am very optimistic about the future development of Kechuang Biotechnology.
There's only one problem, it's too expensive. This is not Kechuang Biotech’s problem, it’s my problem. "
After the preview of Kechuang Biotech's 2022 annual report was released, it aroused heated discussion in the capital market.
The net profit of RMB 150 billion is very high, but there are still higher companies ahead.
However, the only two domestic giants that have achieved such high net profits are Goose Factory and Ali.
Only Goose Factory has maintained a growth trend. It has been in a growth trend. Although the growth rate has slowed down, it is still rising.
Ali's full-year net profit in 2019 was 163.3 billion RMB, and its full-year net profit in 2020 was 151.2 billion RMB. In 2021, its full-year net profit was only 71.1 billion RMB.
It is precisely because of negative growth that Ali's market value fell from 5 trillion hkd to less than 1 trillion hkd.
As a rising star, Kechuang Biotech’s net profit exceeded 150 billion RMB in just four years.
Net profit growth has remained above 100% in consecutive years, and the secondary market is infinitely promising.
Retail investors couldn't buy it even if they wanted to, and they didn't dare to buy it. It was too expensive, costing 500,000 per lot.
Domestic institutions and European and American investment institutions have been adding positions to raise funds.
Technology creates wealth, but creating wealth in this way still gives Chinese entrepreneurs a big impact.
The impact it has had on the industry is comparable to the time when Alipay helped Tianhong sell Yu’e Bao, which transformed it from an unknown small fund company into the largest fund company. The scale of Yu’e Bao alone exceeded one trillion.
Affected by this, angel investors in China prefer R&D companies to Internet companies.
In the past two years, Internet companies have been having an increasingly difficult time, and even Ali’s net profit has inevitably plummeted, let alone start-ups.
It has become increasingly difficult to obtain a large number of users through subsidies, expand the scale and then go public to make money.
"How to see Kechuang Biotech's 2022 full-year financial report?"
Since the company has money, it does not need to squeeze bottom-level employees to gain profits. Therefore, Kechuang Biotech basically does not work overtime, and performance appraisals do not look at your working hours.
In addition, Kechuang Biotechnology has been very friendly to graduates of biology, materials science, and chemistry in recruiting over the years, and three of the four major tiankeng majors accounted for it.
Science and Technology Biotechnology not only recruits a lot, but also offers a lot. Of course, the requirements are also high.
Therefore, issues related to scientific and innovative biology have always been highly discussed on Zhihu.
“Thank you for the invitation. As a PhD student in biology who was recruited into Kechuang Biotech through the school this year, let’s talk about why Kechuang Biotech can achieve such high profits.
First of all, the R&D team of Kechuang Biotechnology is very large. The R&D team of the Suzhou R&D Center has more than 3,000 people, more than one-third of whom are Ph.D.
There are about a thousand people in Jiangcheng, about a thousand people in Lion City, and about eight hundred people in the R&D center in England.
The proportion of PhD students in Lion City and England is about 50%, while the proportion of PhD students in Jiangcheng and Suzhou is about the same.
Kechuang Biotech spends almost 30 billion on labor costs every year.
The treatment given to R&D personnel is comparable to that of programmers from large manufacturers. Their working hours far exceed ours. We basically don’t have to work overtime, let alone small and long weeks.
The scientific research atmosphere is very good. No matter which direction you have ideas, you can find people in the corresponding direction in the internal system to discuss with you. Of course it's limited to the biological aspects I work on.
At present, Kechuang Biotech's main source of profit is the research and development results of Dr. Zheng, endorphins and brain-computer connection.
Among them, the brain-computer connection is mainly handled by the R&D team in the Lion City, because Director Zheng himself is also in the Lion City. Whether it is a brain-computer connection to a mobile phone or a brain-computer connection to a VR, all research and development tasks are placed in the Lion City.
The R&D centers in Suzhou and Jiangcheng are mainly engaged in optimizing the industrial production process of endorphins, and have currently reduced costs by 20%.
In addition, it mainly focuses on the research and development of innovative drugs. Currently, the two domestic R&D centers combined have 13 innovative drug pipelines in progress.
It is very shameful that innovative drugs have not yet created profits.
The R&D center in England mainly produces AI chips and AI algorithms. It is said that this R&D center will be allocated to Kechuang Semiconductor later. Kechuang Semiconductor is a subsidiary established only last year. It mainly produces brain-computer connection chips.
Our investment in scientific research is absolutely very high, and our R&D investment is second only to Huawei. "
